AZN three-lens brief
Evidence-based stock research on AZN. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 11.8pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 11.8pp over 30 days.
- Analyst mean target $212.54 — 33% above current (11 analysts).
AZN closed at $159.64 (+1.72%) as of 2026-09-11. Market cap: $247.58B. P/E (trailing) 23.5. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $212.54 — 33% above current (11 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 11.8pp over 30 days.. Last quarter: Revenue $15.38B, net income $2.51B, free cash flow $4.91B.
Why three lenses on AZN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AZNacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AZN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AZN brief"></iframe>